KROS vs TOI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
KROS presents a stark dichotomy between a perfect Piotroski F-Score (9/9) and collapsing fundamental growth. While the balance sheet is exceptionally strong with a current ratio of 15.45 and minimal debt, the company is experiencing a severe revenue contraction of -87.30% and extreme operating losses. The stock is significantly undervalued relative to its Graham Number ($28.33) and Intrinsic Value ($16.1), but this value is offset by bearish insider activity and a negative technical trend.
The Oncology Institute (TOI) exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price/Book ratio of -22.14, indicating negative shareholders' equity. While the company shows impressive top-line revenue growth of 41.60% YoY, it remains unprofitable with negative operating and profit margins. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual financial health and bearish insider selling patterns. The lack of a Graham Number or Altman Z-Score further underscores the company's distressed financial state.
Compare Another Pair
Related Comparisons
KROS vs TOI: Head-to-Head Comparison
This page compares Keros Therapeutics, Inc. (KROS) and The Oncology Institute, Inc. (TOI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.